The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...

Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

For decades, RAS was considered undruggable, off limits. That changed once the first inhibitors were discovered targeting the KRAS-G12C mutation. Those molecules showed initial proof-of-concept ...

Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...

Certain co-existing mutations may contribute to resistance to KRAS G12C inhibitors among patients with colorectal and pancreatic cancers, a cohort study showed. (Clinical Cancer Research ...